Cargando…
Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
BACKGROUND: Bipolar disorder (BPD) is prevalent and is associated with a significant economic burden. Asenapine, the first tetracyclic antipsychotic approved in Canada for the treatment of BPD, has shown a comparable efficacy profile to other atypical antipsychotics. In addition, it is associated wi...
Autores principales: | Lachaine, Jean, Beauchemin, Catherine, Mathurin, Karine, Gilbert, Dominique, Beillat, Maud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905654/ https://www.ncbi.nlm.nih.gov/pubmed/24450548 http://dx.doi.org/10.1186/1471-244X-14-16 |
Ejemplares similares
-
Asenapine for bipolar disorder
por: Scheidemantel, Thomas, et al.
Publicado: (2015) -
Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD
por: Lachaine, Jean, et al.
Publicado: (2016) -
A Review of Asenapine in the Treatment of Bipolar Disorder
por: Vieta, Eduard, et al.
Publicado: (2017) -
Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context
por: Caresano, Chiara, et al.
Publicado: (2014) -
Asenapine augmentation in bipolar disorders: a case series
por: Marazziti, Donatella, et al.
Publicado: (2016)